Cara Therapeutics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Cara Therapeutics (CARA) Misses Q2 EPS by 6c
August 4, 2016 4:36 PM EDTCara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.48), $0.06 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $79 thousand versus the consensus estimate of $130 thousand.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More